Session » SLE – Treatment Poster (1732–1772)

Date: Tuesday, November 9, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 1768

Additional Hydroxychloroquine Therapy Regulates Adipokines in Systemic Lupus Erythematosus with Stable Disease Activity

8:30AM-10:30AM: Abstract Number: 1759

An Analysis of Medication Responsiveness Based on Subtype and Race Within a Cohort of Cutaneous Lupus Erythematosus Patients

8:30AM-10:30AM: Abstract Number: 1741

Anifrolumab Results in Favorable Responses Regardless of SLE Disease Duration: Post Hoc Analysis of Data from 2 Phase 3 Trials

8:30AM-10:30AM: Abstract Number: 1772

Autologous EBV-specific Cytotoxic T Cells in Systemic Lupus Erythematosus: An Innovative Phase I/IIa Clinical Trial

8:30AM-10:30AM: Abstract Number: 1746

Baricitinib Decreases Anti-dsDNA and IgG Antibodies in Adults with Systemic Lupus Erythematosus from a Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial

8:30AM-10:30AM: Abstract Number: 1763

Baricitinib Reduces Proinflammatory Serum Cytokines in Patients with Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 1747

BIIB059 Demonstrates Improvement in Joint Manifestations in Participants with Systemic Lupus Erythematosus in Part a of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

8:30AM-10:30AM: Abstract Number: 1769

BMS-986256, an Oral Novel Toll-like Receptor 7 and 8 (TLR7/8) Inhibitor, Does Not Affect the Pharmacokinetics of Mycophenolate Mofetil in Healthy Subjects

8:30AM-10:30AM: Abstract Number: 1756

Class V Systemic Lupus Erythematosus Nephritis Patients Are Undertreated and Face Similar Adverse Renal Outcomes as Class III/IV Patients

8:30AM-10:30AM: Abstract Number: 1733

Classification of Patients with Systemic Lupus Erythematosus Enrolled in 2 Phase 3 Trials by EULAR/ACR 2019 Criteria

8:30AM-10:30AM: Abstract Number: 1757

Clinical Use of Belimumab for Systemic Lupus Erythematosus in the Setting of Advanced Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: A Case Series

8:30AM-10:30AM: Abstract Number: 1761

Comparison of Belimumab and Standard of Care by Inverse Probability of Treatment Weighting Analyses Based on Propensity Score in Patients with Systemic Lupus Erythematosus in the Maintenance Phase

8:30AM-10:30AM: Abstract Number: 1767

CXCL5 Dampens Inflammation in Murine Lupus by Orchestral Suppression of Effector Cell Proliferation and Leukocyte Extravasation

8:30AM-10:30AM: Abstract Number: 1734

Efavaleukin Alfa, a Novel IL-2 Mutein, Selectively Expands Regulatory T Cells in Patients with SLE: Interim Results of a Phase 1b Multiple Ascending Dose Study

8:30AM-10:30AM: Abstract Number: 1754

Effect of Belimumab on Autoantibodies, Complement, and B-Cell Subsets in Patients with Lupus Nephritis

8:30AM-10:30AM: Abstract Number: 1732

Effects of B Cell Activating Factors/B Lymphocyte Stimulator Inhibitors Added to Standard of Care on Infection in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

8:30AM-10:30AM: Abstract Number: 1740

Efficacy of Anifrolumab in Patients with SLE Previously Treated with Biologics: Post Hoc Analysis of Data from 2 Phase 3 Trials

8:30AM-10:30AM: Abstract Number: 1742

Efficacy of Anifrolumab in Serological Subgroups of Patients with SLE Participating in 2 Phase 3 Trials

8:30AM-10:30AM: Abstract Number: 1752

Efficacy of Voclosporin in Recent Onset Lupus Nephritis

8:30AM-10:30AM: Abstract Number: 1764

Estimation of the Prevalence of Hydroxychloroquine-Induced Retinopathy in a Cohort of Hydroxychloroquine-Compliant Patients

8:30AM-10:30AM: Abstract Number: 1771

First-in-Human Safety, Pharmacokinetic and Pharmacodynamic Study of Escalating Single- and Multiple-Doses of BMS-986256, a Novel, Potent, Oral Inhibitor of TLR7 and TLR8

8:30AM-10:30AM: Abstract Number: 1735

Glucocorticoid Discontinuation in Patients with Systemic Lupus Erythematosus with Prior Severe Organ Manifestation

8:30AM-10:30AM: Abstract Number: 1762

Hydroxychloroquine Alone Does Not Increase QTc in the Absence of Other QT-prolonging Medications

8:30AM-10:30AM: Abstract Number: 1753

Hydroxychloroquine Blood Levels Are Associated with Reduced SLE Disease Activity and Improvements in Cardiovascular Risk Factors

8:30AM-10:30AM: Abstract Number: 1744

Improvement of Renal and Non-Renal SLE Outcome Measures on Sirolimus Therapy – a 21-year Follow-up Study of 73 Patients

8:30AM-10:30AM: Abstract Number: 1755

Increasing Participation of Underrepresented Groups in Lupus Clinical Trials: Insights from Qualitative Interviews with Patients and Physicians

8:30AM-10:30AM: Abstract Number: 1770

Interim Analysis of Cohort 1 in the Mesenchymal Stromal Cell Trial in Systemic Lupus Erythematosis: Safety and Data Management During the Pandemic

8:30AM-10:30AM: Abstract Number: 1766

Itolizumab-induced Modulation of Cell Surface CD6 Is a Pharmacodynamic Marker of Drug Activity in SLE Patients

8:30AM-10:30AM: Abstract Number: 1750

Itolizumab, a Novel anti-CD6 Therapy, in Systemic Lupus Erythematosus Patients: Interim Safety Results from the Phase 1b EQUALISE Dose-escalation Study

8:30AM-10:30AM: Abstract Number: 1760

Long-term Opioid Use Among Patients with Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 1745

Pre-pregnancy Switching from Mycophenolate to Azathioprine in Patients with Lupus Nephritis: A Retrospective Outcome Analysis

8:30AM-10:30AM: Abstract Number: 1737

Reduction in Urinary CD163 Is Associated with Treatment Response in the Belimumab Lupus Nephritis Trial

8:30AM-10:30AM: Abstract Number: 1765

Should SLE Patients Entering Clinical Trials Be Required to Have at Least One BILAG A and/or Two BILAG B Domain Scores?

8:30AM-10:30AM: Abstract Number: 1739

SLE Treatment History and Anifrolumab Efficacy by Baseline Standard Therapies in Patients with SLE from 2 Phase 3 Trials

8:30AM-10:30AM: Abstract Number: 1748

The Peroxisome Proliferator-Activated Receptor-γ (PPAR) Agonist Pioglitazone Improves Vascular and Metabolic Dysfunction in Patients with Systemic Lupus Erythematosus (SLE)

8:30AM-10:30AM: Abstract Number: 1736

Treatment of Lupus Nephritis with Belimumab Is Associated with Reduction in Urinary CD23

8:30AM-10:30AM: Abstract Number: 1749

Treatment Patterns in Latin American Patients with Lupus Nephritis over a 20-year Period

8:30AM-10:30AM: Abstract Number: 1738

Uveitis Status in Patients with Ankylosing Spondylitis or Psoriatic Arthritis Under Secukinumab Treatment – Real World Data from a German Observational Study

8:30AM-10:30AM: Abstract Number: 1751

Voclosporin Is Effective in Achieving Complete Renal Response Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials

8:30AM-10:30AM: Abstract Number: 1743

Whole Blood Hydroxychloroquine Levels Do Not Correlate with QTc Intervals in a Cohort of 84 SLE Patients: Evidence That Antimalarials Are Not Associated with Cardiac Conduction System Toxicity

8:30AM-10:30AM: Abstract Number: 1758

WITHDRAWN

« View all sessions from this meeting